Skip to main content
Rapid Reactions

HER2Climb Study Represents an Important Breakthrough for Patients with HER2-positive Metastatic Breast Cancer

Hatem Soliman, MD
Medical Director of the Clinical Trials Office
Moffitt Cancer Center Tampa, Florida
The long-term results of the HER2Climb trial, which compared TUKYSA® (tucatinib) to trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer (mBC) with and without brain metastases, were presented at ASCO this year. The results generated a significant amount of interest among physicians who manage women with HER2-positive mBC. Please join Hatem Soliman, MD, from The Center for Women's Oncology at Moffitt Cancer Center, as he discusses some of the pivotal data from the HER2Climb trial at ASCO this year.

Related Items